{"id":52959,"date":"2023-01-16T20:02:30","date_gmt":"2023-01-16T19:02:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lidocaine-ointment-market-report-2022-increasing-research-and-development-drives-growth-researchandmarkets-com\/"},"modified":"2023-01-16T20:02:30","modified_gmt":"2023-01-16T19:02:30","slug":"lidocaine-ointment-market-report-2022-increasing-research-and-development-drives-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lidocaine-ointment-market-report-2022-increasing-research-and-development-drives-growth-researchandmarkets-com\/","title":{"rendered":"Lidocaine Ointment Market Report 2022: Increasing Research and Development Drives Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Lidocaine Ointment Market, by Formulation, by Age Group, by Application, by Distribution Channel, by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nTopical lidocaine ointment is used on various parts of the body to cause loss of sensation in patients undergoing certain medical procedures, such as surgery. It is also used to relieve pain and itching caused by conditions such as sun burn, poison ivy, poison oak, minor cuts and abrasions. It is also used to prevent and control pain during urethral surgery in both men and women.\n<\/p>\n

\nLidocaine is a local anesthetic commonly used for local anesthesia, but it is also used as an antiarrhythmic and analgesic drug and also used as an adjutant to endotracheal intubation. It is a tertiary amine and an antiarrhythmic drug according to the Vaughan-Williams classification. Lidocaine acts as a valuable tool in anesthesiology, cardiology, and pain management. In plasma, lidocaine has 65% of its protein bound to albumin and alpha 1 acid glycoprotein, giving it an intermediate duration of action compared to other local anesthetics. Lidocaine ointment are used to numb the lining of the mouth or throat before certain medical\/dental procedures.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nThe increasing research and development activities of lidocaine ointment for product expansion by the key players in the market, which is expected to drive the market growth over the forecast period. For instance, in January 2021, The Mayo Clinic in Arizona has initiated a clinical study comparing two local anesthetics for fractional non-ablative laser treatment of the face. 2.5 g lidocaine 23%\/tetracaine 7% ointment is in Phase 2 and 7.5 g lidocaine 2.5%\/prilocaine 2.5% cream is in Phase 3 clinical trials. The scheduled completion date is January 2023.\n<\/p>\n

\nKey Features of the Study:<\/strong>\n<\/p>\n